{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T12:20:58Z","timestamp":1790511658467,"version":"4.1.0"},"publisher-location":"Cham","reference-count":83,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783030404635","type":"print"},{"value":"9783030404642","type":"electronic"}],"license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019]]},"DOI":"10.1007\/10_2019_107","type":"book-chapter","created":{"date-parts":[[2019,8,24]],"date-time":"2019-08-24T17:02:34Z","timestamp":1566666154000},"page":"155-188","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Advances in Vaccines"],"prefix":"10.1007","author":[{"given":"Helen H.","family":"Mao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoubai","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,25]]},"reference":[{"key":"107_CR1","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/S1473-3099(18)30310-4","volume":"18","author":"GBD 2016 Lower Respiratory Infections Collaborators","year":"2018","unstructured":"GBD 2016 Lower Respiratory Infections Collaborators (2018) Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect Dis 18:1191\u20131210","journal-title":"Lancet Infect Dis"},{"key":"107_CR2","doi-asserted-by":"publisher","first-page":"6707","DOI":"10.1016\/j.vaccine.2016.10.025","volume":"34","author":"M Doherty","year":"2016","unstructured":"Doherty M et al (2016) Vaccine impact: benefits for human health. Vaccine 34:6707\u20136714","journal-title":"Vaccine"},{"key":"107_CR3","unstructured":"WHO. https:\/\/www.who.int\/immunization\/research\/vaccine_pipeline_tracker_spreadsheet . Accessed 25 Apr 2019"},{"key":"107_CR4","unstructured":"WHO (2014) European vaccine action plan 2015\u20132020. http:\/\/www.euro.who.int\/en\/health-topics\/disease-prevention\/vaccines-and-immunization\/publications\/2014\/european-vaccine-action-plan-20152020-2014"},{"key":"107_CR5","unstructured":"China CDC. www.china.cdc.cn . Accessed 12 Apr 2019"},{"key":"107_CR6","unstructured":"USCDC. www.CDC.gov . Accessed 25 Apr 2019"},{"key":"107_CR7","unstructured":"WHO report on Measles. www.who.int . Accessed 12 Apr 2019"},{"key":"107_CR8","volume-title":"European Centre for Disease Prevention and Control, annual epidemiological report for 2017","author":"EMA","year":"2019","unstructured":"EMA (2019) European Centre for Disease Prevention and Control, annual epidemiological report for 2017. ECDC, Stockholm"},{"key":"107_CR9","doi-asserted-by":"publisher","first-page":"e1386","DOI":"10.1016\/S2214-109X(18)30346-2","volume":"6","author":"D Gouglas","year":"2018","unstructured":"Gouglas D, Le TT et al (2018) Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study. Lancet Glob Health 6:e1386\u2013e1396","journal-title":"Lancet Glob Health"},{"key":"107_CR10","doi-asserted-by":"publisher","first-page":"A2","DOI":"10.1016\/j.vaccine.2016.10.085","volume":"35","author":"A Mahmoud","year":"2017","unstructured":"Mahmoud A et al (2017) Achieving a \u201cGrand Convergence\u201d in global health by 2035. Vaccine 35:A2\u2013A5","journal-title":"Vaccine"},{"key":"107_CR11","unstructured":"USCDC. www.uscdc.gov . Accessed 27 Apr 2019"},{"key":"107_CR12","unstructured":"USFDA (2017) Encouraging vaccine innovation: promoting the development of vaccines that minimize the burden of infectious diseases in the 21st century report to congress. www.fda.gov"},{"key":"107_CR13","doi-asserted-by":"publisher","first-page":"6691","DOI":"10.1016\/j.vaccine.2016.10.078","volume":"34","author":"K Hardt","year":"2016","unstructured":"Hardt K et al (2016) Vaccine strategies: optimising outcomes. Vaccine 34:6691\u20136699","journal-title":"Vaccine"},{"key":"107_CR14","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.vaccine.2017.11.019","volume":"34","author":"H Lal","year":"2018","unstructured":"Lal H et al (2018) Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: results of a phase III, randomized, open-label, multicenter. Vaccine 34:148\u2013154","journal-title":"Vaccine"},{"key":"107_CR15","unstructured":"WHO Website. www.who.int . Accessed 2 Apr 2019"},{"key":"107_CR16","doi-asserted-by":"publisher","first-page":"4064","DOI":"10.1016\/j.vaccine.2017.06.003","volume":"35","author":"S Plotkin","year":"2017","unstructured":"Plotkin S et al (2017) The complexity and cost of vaccine manufacturing \u2013 an overview. Vaccine 35:4064\u20134071","journal-title":"Vaccine"},{"issue":"8","key":"107_CR17","doi-asserted-by":"publisher","first-page":"e0135009","DOI":"10.1371\/journal.pone.0135009","volume":"10","author":"M Jeyanathan","year":"2015","unstructured":"Jeyanathan M, Shao Z, Yu X, Harkness R et al (2015) AdHu5Ag85A respiratory mucosal boost immunization enhances protection against pulmonary tuberculosis in BCG-primed non-human primates. PLoS One 10(8):e0135009","journal-title":"PLoS One"},{"key":"107_CR18","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1056\/NEJMoa1414216","volume":"376","author":"JA Regules","year":"2014","unstructured":"Regules JA et al (2014) A recombinant vesicular stomatitis virus Ebola vaccine. N Engl J Med 376:330\u2013341","journal-title":"N Engl J Med"},{"key":"107_CR19","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.vaccine.2011.11.067","volume":"30","author":"HJ Sharmaa","year":"2012","unstructured":"Sharmaa HJ et al (2012) Assessment of safety and immunogenicity of two different lots of diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae type b vaccine manufactured using small and large scale manufacturing process. Vaccine 30:510\u2013516","journal-title":"Vaccine"},{"key":"107_CR20","unstructured":"USFDA, FDA Guidance (2010) Characterization and qualification of cell substrates and other biological materials used in the production of viral vaccines for infectious disease indications. www.fda.gov\/BiologicsBloodVaccine\/guidence"},{"key":"107_CR21","unstructured":"USFDA. FDA guidance for industry providing clinical evidence of effectiveness for human drug and biological products. Accessed 18 Apr 2019"},{"issue":"9984","key":"107_CR22","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1016\/S0140-6736(15)60553-0","volume":"385","author":"FC Zhu","year":"2015","unstructured":"Zhu FC, Hou LH, Li JX et al (2015) Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet 385(9984):2272\u20132279","journal-title":"Lancet"},{"issue":"9","key":"107_CR23","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1080\/21645515.2017.1342021","volume":"13","author":"L Wu","year":"2017","unstructured":"Wu L, Zhang Z, Gao H et al (2017) Open-label phase I clinical trial of Ad5-EBOV in Africans in China. Hum Vaccin Immunother 13(9):2078\u20132085","journal-title":"Hum Vaccin Immunother"},{"issue":"10069","key":"107_CR24","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/S0140-6736(16)32617-4","volume":"389","author":"FC Zhu","year":"2017","unstructured":"Zhu FC, Wurie AH, Hou LH et al (2017) Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 389(10069):621\u2013628","journal-title":"Lancet"},{"key":"107_CR25","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1016\/j.vaccine.2018.02.029","volume":"36","author":"M Kovac","year":"2018","unstructured":"Kovac M et al (2018) Complications of herpes zoster in immunocompetent older adults: incidence in vaccine and placebo groups in two large phase 3 trials. Vaccine 36:1537\u20131541","journal-title":"Vaccine"},{"key":"107_CR26","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1093\/infdis\/jit365","volume":"208","author":"R Chlibek","year":"2013","unstructured":"Chlibek R et al (2013) Safety and immunogenicity of an AS01-adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults \u226550 years of age. J Infect Dis 208:1953","journal-title":"J Infect Dis"},{"key":"107_CR27","unstructured":"USFDA (1997) FDA guidance for industry, for the evaluation of combination vaccines for preventable diseases: production, testing and clinical studies. Accessed 10 Apr 2019"},{"key":"107_CR28","unstructured":"WHO. WHO website. www.who.int . Accessed 23 Apr 2019"},{"key":"107_CR29","volume-title":"FDA guidance for industry general principles for the development of vaccines to protect against global infectious diseases","author":"USFDA","year":"2011","unstructured":"USFDA (2011) FDA guidance for industry general principles for the development of vaccines to protect against global infectious diseases"},{"key":"107_CR30","unstructured":"21 CFR Part 601, Subpart H. https:\/\/www.law.cornell.edu\/cfr\/text\/21\/part-314\/subpart-H . Accessed 22 Apr 2019"},{"key":"107_CR31","unstructured":"USFDA. Biothrax vaccine. https:\/\/www.fda.gov\/vaccines-blood-biologics\/vaccines\/biothrax . Accessed 3 Apr 2019"},{"issue":"4","key":"107_CR32","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1177\/2051013615599151","volume":"3","author":"RW Johnson","year":"2015","unstructured":"Johnson RW et al (2015) Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective. Ther Adv Vaccines 3(4):109\u2013120","journal-title":"Ther Adv Vaccines"},{"key":"107_CR33","unstructured":"Shingrix Product Insert. www.fda.gov . Accessed 26 Mar 2019"},{"key":"107_CR34","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.vaccine.2014.12.024","volume":"33","author":"J Diez-Domingo","year":"2015","unstructured":"Diez-Domingo J et al (2015) Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged \u226550 years: a randomised non-inferiority clinical trial. Vaccine 33:789\u2013795","journal-title":"Vaccine"},{"issue":"15","key":"107_CR35","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1056\/NEJMoa1404505","volume":"371","author":"S Baize","year":"2014","unstructured":"Baize S, Pannetier D, Oestereich L et al (2014) Emergence of Zaire Ebola virus disease in Guinea. N Engl J Med 371(15):1418\u20131425","journal-title":"N Engl J Med"},{"issue":"9950","key":"107_CR36","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1016\/S0140-6736(14)61706-2","volume":"384","author":"AJ Kucharski","year":"2014","unstructured":"Kucharski AJ, Edmunds WJ (2014) Case fatality rate for Ebola virus disease in West Africa. Lancet 384(9950):1260","journal-title":"Lancet"},{"key":"107_CR37","unstructured":"WHO (2014) Ebola virus disease. http:\/\/www.who.int\/mediacentre\/factsheets\/fs103\/en\/ . Accessed 23 Mar 2019"},{"issue":"3","key":"107_CR38","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/15376510802312464","volume":"5","author":"RL Sheets","year":"2008","unstructured":"Sheets RL, Stein J, Bailer RT et al (2008) Biodistribution and toxicological safety of adenovirus type 5 and type 35 vectored vaccines against human immunodeficiency virus-1 (HIV-1), Ebola, Marburg are similar despite differing adenovirus serotype vector, manufacturer\u2019s construct, gene inserts. J Immunotoxicol 5(3):315\u2013335","journal-title":"J Immunotoxicol"},{"key":"107_CR39","unstructured":"USFDA. Bexsero product insert. www.fda.gov . Accessed 27 Mar 2019"},{"key":"107_CR40","unstructured":"USFDA. Trmenba product insert. www.fda.gov . Accessed 27 Mar 2019"},{"key":"107_CR41","unstructured":"USCDC. www.uscdc.gov . Accessed 27 Mar 2019"},{"key":"107_CR42","unstructured":"USFDA (2016) Gardasil 9 product insert. www.fda.gov"},{"key":"107_CR43","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/nature12060","volume":"496","author":"S Bhatt","year":"2013","unstructured":"Bhatt S, Gething PW, Brady OJ et al (2013) The global distribution and burden of dengue. Nature 496:504\u2013507","journal-title":"Nature"},{"key":"107_CR44","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1001\/jama.2007.31-a","volume":"299","author":"DM Morens","year":"2008","unstructured":"Morens DM, Fauci AS et al (2008) Dengue and hemorrhagic fever: a potential threat to public health in the United States. JAMA 299:214\u2013216","journal-title":"JAMA"},{"key":"107_CR45","unstructured":"WHO. Dengue and dengue haemorrhagic fever, Fact sheet No.117. http:\/\/www.who.int\/mediacentre\/factsheets\/fs117\/en\/ . Revised Apr 2016"},{"key":"107_CR46","volume-title":"Dengue: guidelines for diagnosis, treatment, prevention and control: new edition. Geneva 2009","author":"WHO","year":"2014","unstructured":"WHO (2014) Dengue: guidelines for diagnosis, treatment, prevention and control: new edition. Geneva 2009. WHO, Geneva"},{"key":"107_CR47","volume-title":"Dengue vaccine, VRBPAC briefing document","author":"USFDA","year":"2019","unstructured":"USFDA (2019) Dengue vaccine, VRBPAC briefing document. www.fda.gov"},{"key":"107_CR48","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/j.1574-6976.2002.tb00601.x","volume":"26","author":"PC McMinn","year":"2002","unstructured":"McMinn PC et al (2002) An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev 26:91\u2013107","journal-title":"FEMS Microbiol Rev"},{"key":"107_CR49","doi-asserted-by":"publisher","first-page":"3516","DOI":"10.1016\/j.vaccine.2010.03.003","volume":"28","author":"J Xu","year":"2010","unstructured":"Xu J, Qian Y, Wang S, Serrano JMG, Li W, Huang Z et al (2010) EV71: an emerging infectious disease vaccine target in the far east? Vaccine 28:3516\u20133521","journal-title":"Vaccine"},{"key":"107_CR50","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1016\/j.vaccine.2012.03.010","volume":"30","author":"YP Li","year":"2012","unstructured":"Li YP, Liang ZL, Gao Q, Huang LR, Mao QY, Wen SQ et al (2012) Safety and immunogenicity of a novel human enterovirus 71 (EV71) vaccine: a randomized, placebo-controlled, double-blind, phase I clinical trial. Vaccine 30:3295\u20133303","journal-title":"Vaccine"},{"issue":"9","key":"107_CR51","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1056\/NEJMoa1304923","volume":"370","author":"F Zhu","year":"2014","unstructured":"Zhu F et al (2014) Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med 370(9):818\u2013828","journal-title":"N Engl J Med"},{"issue":"12","key":"107_CR52","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.4161\/hv.21739","volume":"8","author":"P Chong","year":"2012","unstructured":"Chong P et al (2012) Production of EV71 vaccine candidates. Hum Vaccin Immunother 8(12):1775\u20131783","journal-title":"Hum Vaccin Immunother"},{"key":"107_CR53","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/S1473-3099(10)70194-8","volume":"10","author":"T Solomon","year":"2010","unstructured":"Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH (2010) Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis 10:778\u2013790","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"107_CR54","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1093\/cid\/ciu852","volume":"60","author":"P Chone","year":"2015","unstructured":"Chone P et al (2015) Review of enterovirus 71 vaccines. Clin Infect Dis 60(5):797\u2013780","journal-title":"Clin Infect Dis"},{"issue":"1","key":"107_CR55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0210553","volume":"14","author":"CY Wu","year":"2019","unstructured":"Wu CY et al (2019) The mature EV71 virion induced a broadly cross-neutralizing VP1 antibody against subtypes of the EV71 virus. PLoS One 14(1):e0210553","journal-title":"PLoS One"},{"key":"107_CR56","unstructured":"Vaccines and Related Biological Products Advisory Committee Meeting July 28, 2017. FDA briefing document heplisav-B (Hepatitis B vaccine recombinant and 1018 ISS adjuvant). www.fda.gov"},{"key":"107_CR57","unstructured":"Heplisav-B Product Insert. www.USFDA.gov . Accessed 12 Apr 2019"},{"issue":"37","key":"107_CR58","doi-asserted-by":"publisher","first-page":"4024","DOI":"10.1016\/j.vaccine.2013.05.014","volume":"31","author":"RK Kuan","year":"2013","unstructured":"Kuan RK et al (2013) Cost-effectiveness of hepatitis B vaccination using HEPLISAV\u2122 in selected adult populations compared to Engerix-B\u00ae vaccine. Vaccine 31(37):4024\u20134032","journal-title":"Vaccine"},{"issue":"12","key":"107_CR59","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.4161\/hv.7.12.18333","volume":"7","author":"CL Gilbert","year":"2011","unstructured":"Gilbert CL et al (2011) Safety and immunogenicity of a modified process hepatitis B vaccine in healthy adults \u226550 years. Hum Vaccin 7(12):1336\u20131342","journal-title":"Hum Vaccin"},{"issue":"7","key":"107_CR60","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1358\/dot.2018.54.7.2833984","volume":"54","author":"LM Splawn","year":"2018","unstructured":"Splawn LM et al (2018) Heplisav-B vaccination for the prevention of hepatitis B virus infection in adults in the United States. Drugs Today (Barc) 54(7):399\u2013405","journal-title":"Drugs Today (Barc)"},{"key":"107_CR61","doi-asserted-by":"publisher","first-page":"6700","DOI":"10.1016\/j.vaccine.2017.10.017","volume":"35","author":"A Strezova","year":"2017","unstructured":"Strezova A et al (2017) A randomized lot-to-lot immunogenicity consistency study of the candidate zoster vaccine HZ\/su. Vaccine 35:6700\u20136706","journal-title":"Vaccine"},{"key":"107_CR62","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/S1473-3099(17)30541-8","volume":"7","author":"PS Gsell","year":"2017","unstructured":"Gsell PS, Camacho A et al (2017) Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016: an operational and vaccine safety report. Lancet Infect Dis 7:1276\u20131128","journal-title":"Lancet Infect Dis"},{"key":"107_CR63","doi-asserted-by":"crossref","unstructured":"Daouda Sissoko BD et al Resurgence of Ebola virus disease in guinea linked to a survivor with virus persistence in seminal fluid for more than 500 days. Clin Infect Dis 63(10):1353\u20131356","DOI":"10.1093\/cid\/ciw601"},{"key":"107_CR64","unstructured":"Medaglini D et al Correlates of vaccine-induced protective immunity against Ebola virus disease. Seminars in immunology. Academic Press, Cambridge"},{"key":"107_CR65","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","volume":"380","author":"R Lozano","year":"2012","unstructured":"Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V et al (2012) Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet 380:2095\u20132128","journal-title":"Lancet"},{"key":"107_CR66","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa043951","volume":"352","author":"AR Falsey","year":"2005","unstructured":"Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE (2005) Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 352:1749\u20131759","journal-title":"N Engl J Med"},{"key":"107_CR67","doi-asserted-by":"publisher","first-page":"92","DOI":"10.2174\/187152612800100099","volume":"12","author":"CB Hall","year":"2012","unstructured":"Hall CB et al (2012) The burgeoning burden of respiratory syncytial virus among children. Infect Disord Drug Targets 12:92\u201397","journal-title":"Infect Disord Drug Targets"},{"key":"107_CR68","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1128\/CMR.11.3.430","volume":"11","author":"RA Dudas","year":"1998","unstructured":"Dudas RA, Karron RA (1998) Respiratory syncytial virus vaccines. Clin Microbiol Rev 11:430\u2013439","journal-title":"Clin Microbiol Rev"},{"key":"107_CR69","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/S0140-6736(10)60206-1","volume":"375","author":"H Nair","year":"2010","unstructured":"Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ et al (2010) Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 375:1545\u20131555","journal-title":"Lancet"},{"key":"107_CR70","volume-title":"Trends in maternal mortality: 1990\u20132010 WHO, UNICEF, UNFPA, and The World Bank estimates","author":"WHO","year":"2012","unstructured":"WHO (2012) Trends in maternal mortality: 1990\u20132010 WHO, UNICEF, UNFPA, and The World Bank estimates. WHO, Geneva. http:\/\/apps.who.int\/iris\/bitstream\/10665\/44874\/1\/9789241503631eng.pdf"},{"issue":"26","key":"107_CR71","doi-asserted-by":"publisher","first-page":"2870","DOI":"10.1016\/j.vaccine.2016.03.109","volume":"34","author":"D Higgins","year":"2016","unstructured":"Higgins D et al (2016) Advances in RSV vaccine research and development - a global agenda. Vaccine 34(26):2870\u20132875","journal-title":"Vaccine"},{"issue":"7","key":"107_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14760584.2017.1333425","volume":"16","author":"T Villafana","year":"2017","unstructured":"Villafana T et al (2017) Passive and active immunization against respiratory syncytial virus for the young and old. Expert Rev Vaccines 16(7):1\u201313","journal-title":"Expert Rev Vaccines"},{"issue":"Suppl 4","key":"107_CR73","doi-asserted-by":"publisher","first-page":"D13","DOI":"10.1016\/j.vaccine.2015.07.091","volume":"33","author":"SL Hoffman","year":"2015","unstructured":"Hoffman SL et al (2015) The march toward malaria vaccines. Vaccine 33(Suppl 4):D13\u2013D23","journal-title":"Vaccine"},{"issue":"5","key":"107_CR74","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/QCO.0000000000000393","volume":"30","author":"KE Lyke","year":"2017","unstructured":"Lyke KE (2017) Steady progress toward a malaria vaccine. Curr Opin Infect Dis 30(5):463\u2013470","journal-title":"Curr Opin Infect Dis"},{"issue":"10","key":"107_CR75","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.4161\/21645515.2014.972764","volume":"10","author":"JG Keitany","year":"2014","unstructured":"Keitany JG et al (2014) Live attenuated pre-erythrocytic malaria vaccine. Hum Vaccine Immunother 10(10):2903\u20132909","journal-title":"Hum Vaccine Immunother"},{"issue":"52","key":"107_CR76","doi-asserted-by":"publisher","first-page":"7452","DOI":"10.1016\/j.vaccine.2015.09.096","volume":"33","author":"TL Richie","year":"2015","unstructured":"Richie TL et al (2015) Progress with Plasmodium falciparum sporozoite (PfSPZ)-based malaria vaccines. Vaccine 33(52):7452\u20137461","journal-title":"Vaccine"},{"issue":"1","key":"107_CR77","doi-asserted-by":"publisher","first-page":"308","DOI":"10.4269\/ajtmh.17-0449","volume":"98","author":"A Olotu","year":"2018","unstructured":"Olotu A, Urbano V, Hamad A, Eka A et al (2018) Advancing global health through development and clinical trials partnerships: a randomized, placebo-controlled, double-blind assessment of safety, tolerability, and immunogenicity of PfSPZ vaccine for malaria in healthy equatoguinean men. Am J Trop Med Hyg 98(1):308\u2013318","journal-title":"Am J Trop Med Hyg"},{"key":"107_CR78","unstructured":"CEPI. Targeting diseases with epidemic potential. CEPI. www.CEPI.net . Accessed 26 Mar 2019"},{"key":"107_CR79","doi-asserted-by":"publisher","first-page":"594","DOI":"10.3389\/fimmu.2019.00594","volume":"10","author":"C Zhang","year":"2019","unstructured":"Zhang C, Maruggi G et al (2019) Advances in mRNA vaccines for infectious diseases. Front Immunol 10:594. https:\/\/doi.org\/10.3389\/fimmu.2019.00594","journal-title":"Front Immunol"},{"key":"107_CR80","unstructured":"WHO (2014) Report \u201cWHO SAGE Vaccine Hesitancy Working Group report\u201d. https:\/\/www.who.int\/immunization\/sage\/meetings\/2014\/october\/SAGE_working_group_revised_report_vaccine_hesitancy.pdf"},{"key":"107_CR81","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1002\/eji.201546178","volume":"46","author":"M Pinti","year":"2016","unstructured":"Pinti M et al (2016) Aging of the immune system: focus on inflammation and vaccination. Eur J Immunol 46:2286\u20132301","journal-title":"Eur J Immunol"},{"key":"107_CR82","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.coi.2014.01.009","volume":"28","author":"SH Kaufmann","year":"2014","unstructured":"Kaufmann SH et al (2014) Challenges and responses in human vaccine development. Curr Opin Immunol 28:18\u201326","journal-title":"Curr Opin Immunol"},{"key":"107_CR83","doi-asserted-by":"publisher","first-page":"6655","DOI":"10.1016\/j.vaccine.2016.10.016","volume":"34","author":"AL Cunningham","year":"2016","unstructured":"Cunningham AL et al (2016) Vaccine development: from concept to early clinical testing. Vaccine 34:6655\u20136664","journal-title":"Vaccine"}],"container-title":["Advances in Biochemical Engineering\/Biotechnology","Current Applications of Pharmaceutical Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/10_2019_107","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T09:49:56Z","timestamp":1664185796000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/10_2019_107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"ISBN":["9783030404635","9783030404642"],"references-count":83,"URL":"https:\/\/doi.org\/10.1007\/10_2019_107","relation":{},"ISSN":["0724-6145","1616-8542"],"issn-type":[{"value":"0724-6145","type":"print"},{"value":"1616-8542","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019]]},"assertion":[{"value":"25 August 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}